Human Anti-FCGR2B Recombinant Antibody (clone 6G11)
CAT#: HPAB-0535YY
This product is a recombinant human antibody that recognizes (both natural and recombinant) human FCGR2B.
Published Data
Gene Expression
FC
Figure 1 Therapeutic effects of hFcgRII mAb (AT10) and generation of specific mAbs capable of distinguishing hFcgRIIB and hFcgRIIA.
hFcgRIIB mAb binding to hFcgRIIB- (red line) or hFcgRIIA-transfected cells (blue line) and mAb-dependent inhibition of IC binding to hFcgRIIB-transfected cells (green line).
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
FC
Figure 2 Therapeutic effects of hFcgRII mAb (AT10) and generation of specific mAbs capable of distinguishing hFcgRIIB and hFcgRIIA.
Binding profile of mAbs on human leukocyte populations.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Block
Figure 3 hFcgRIIB mAbs are capable of blocking Rituximab engagement with FcgRIIB on the surface of target cells.
Ability of N297Q hFcgRIIB mAbs to block hFcgRIIB ITIM phosphorylation induced by Rit.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Block
Figure 4 hFcgRIIB mAbs are capable of blocking Rituximab engagement with FcgRIIB on the surface of target cells.
Correlation between the ability of hFcgRIIB mAbs to block Rit internalization and their relative ranked affinities (R2 = 0.78).
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Cyt
Figure 5 hFcgRIIB mAb 6G11 has potent cytotoxic activity in vitro and is capable of blocking Rit engagement with hFcgRIIB on the surface of CLL cells.
Cytotoxic ability of 6G11 in ADCP using primary CLL cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
ADCC
Figure 6 hFcgRIIB mAb 6G11 has potent cytotoxic activity in vitro and is capable of blocking Rit engagement with hFcgRIIB on the surface of CLL cells.
Cytotoxic ability of 6G11 in ADCC using primary CLL cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Cyt
Figure 7 hFcgRIIB mAb 6G11 has potent cytotoxic activity in vitro and is capable of blocking Rit engagement with hFcgRIIB on the surface of CLL cells.
CFSE-labeled CLL cells opsonized for 3–4 hr with Rit ± N297Q iso ctrl or 6G11 before co-culture with MDMs. The % of MDMs that have phagocytosed CFSE+ CLL cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
ADCC
Figure 8 hFcgRIIB mAb 6G11 has potent cytotoxic activity in vitro and is capable of blocking Rit engagement with hFcgRIIB on the surface of CLL cells.
CLL cells opsonized with Rit ± N297Q iso ctrl or 6G11 for 3–4 hr before co-culture with NK cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Activ
Figure 9 hFcgRIIB mAb 6G11 is well tolerated and does not result in toxicity.
hFcgRIIB+/3 mFcgRII / mice (six to seven mice/group) were injected with 6G11. The percentage of circulating CD19+ B220+ B cells was assessed.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
ELISA
Figure 10 hFcgRIIB mAb 6G11 is well tolerated and does not result in toxicity.
hFcgRIIB+/3 mFcgRII / mice (six to seven mice/group) were injected with 6G11. Serum 6G11 concentrations were assessed at the indicated times.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
Depletion
Figure 11 hFcgRIIB mAb 6G11 is well tolerated and does not result in toxicity.
In vitro whole blood depletion assay to assess potency of Rit ± WT or N297Q 6G11 in depleting hFcgRIIB+ blood B cells.
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., ... & Smyth, N. R. (2015). Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer cell, 27(4), 473-488.
❮
❯
Normal Tissue
Figure 1 Placenta
Endothelial cells
Staining: High
Intensity: Strong
Quantity: 75%-25%
Hofbauer cells
Staining: High
Intensity: Strong
Quantity: 75%-25%
Syncytiotrophoblasts - cell body
Staining: Medium
Intensity: Moderate
Quantity:>75%
Syncytiotrophoblasts - microvilli
Staining: High
Intensity: Strong
* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/7796/18532_A_3_7.jpg
Normal Tissue
Figure 2 Lymph node
Non-germinal center cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%
Location: Cytoplasmic/membranous
* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/7796/18532_A_8_8.jpg
RNA Expression
Figure 3 RNA cell line category: Cell line enhanced (Daudi, HMC-1, NB-4, RPMI-8226)
Cell lines ordered by descending RNA expression order.
* Image credit: Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000072694-FCGR2B
❮
❯
Specifications
- Host Species
- Human
- Type
- Human IgG1
- Specificity
- Human
- Species Reactivity
- Human
- Clone
- 6G11
- Applications
- FC, Block, Cyt, ADCC, Activ, ELISA, Depletion
- Related Disease
- Cancer
Product Property
- Purity
- >95% as determined by SDS-PAGE and HPLC analysis
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- The FCGR2B antibody has been reported in applications of Flow Cytometry, Blocking, Cytotoxicity, Antibody-dependent Cell-mediated Cytotoxicity, Activation, Enzyme-linked Immunosorbent Assay, Depletion.
Delpetion: 1 mg/kg.
Target
REVIEWS AND Q&AS
CITATIONS
RESOURCES
DOWNLOADS
RELATED PRODUCTS
Inquiry
Navs
Customer Review
There are currently no Customer reviews or questions for HPAB-0535YY. Click the button above to contact us or submit your feedback about this product.
User-Friendly Procedures
This recombinant antibody worked incredibly well when we included it into our multiplex experiments. There was no cross-reactivity with other antibodies and a great signal quality.
Excellent for High Purity Multiplexing
The stability of this antibody amazed me. Its effectiveness was maintained even after being stored for several months.
Stable Over Time
This antibody's high purity reduced background noise in my immunoassays. Knowing that the product satisfies strict quality requirements is comforting.
Q&As
-
How can I verify this antibody's effectiveness in my laboratory?
A: To guarantee reproducibility and specificity of results, validation can be carried out by comparing known positive and negative control samples and employing various detection techniques.
-
How should this antibody be aliquoted for long-term storage?
A: The antibody should ideally be divided into smaller amounts and kept at -20°C or below for storage. By doing this, frequent freeze-thaw cycles that could weaken the antibody are avoided.
-
Which kinds of controls ought to be used in my study?
A: In order to evaluate the specificity and effectiveness of the antibody in your assay, include both positive and negative controls in addition to a control with no primary antibody.
View the frequently asked questions answered by Creative Biolabs Support.
Cite This Product
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# HPAB-0535YY, RRID: AB_3111399)
Copy citation
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number:
See other products for "Clone 6G11"
- CAT
- Product Name
See other products for "FCGR2B"
Select a product category from the dropdown menu below to view related products.
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-267CL | Human Anti-FCGR2B Recombinant Antibody (TAB-267CL) | FC, WB | Human IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-034WM | Human Anti-FCGR2B Recombinant Antibody (TAB-034WM) | ELISA, FC, WB | Human IgG |
| TAB-034WM-S(P) | Human Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-034WM-S(P)) | ELISA, FC, WB | Human scFv |
| TAB-034WM-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-034WM-F(E)) | ELISA, FC, WB | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-035WM | Mouse Anti-FCGR2B Recombinant Antibody (TAB-035WM) | ELISA, FC, Inhib | Mouse IgG |
| TAB-035WM-S(P) | Mouse Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-035WM-S(P)) | ELISA, FC, WB | Mouse scFv |
| TAB-036WM-S(P) | Mouse Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-036WM-S(P)) | ELISA, FC, WB | Mouse scFv |
| TAB-035WM-F(E) | Mouse Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-035WM-F(E)) | ELISA, FC, WB | Mouse Fab |
| TAB-036WM-F(E) | Mouse Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-036WM-F(E)) | ELISA, FC, WB | Mouse Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-037WM | Human Anti-FCGR2B Recombinant Antibody (TAB-037WM) | ELISA, FuncS | Chimeric (human/mouse) IgG |
| TAB-037WM-S(P) | Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-037WM-S(P)) | ELISA, FC, WB | Mouse scFv |
| TAB-037WM-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-037WM-F(E)) | ELISA, FC, WB | Chimeric Antibody (human/mouse) |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-038WM | Human Anti-FCGR2B Recombinant Antibody (TAB-038WM) | ELISA, FuncS | Humanized Antibody |
| TAB-038WM-S(P) | Human Anti-FCGR2B Recombinant Antibody; scFv Fragment (TAB-038WM-S(P)) | ELISA, FC, WB | Humanized scFv |
| TAB-038WM-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (TAB-038WM-F(E)) | ELISA, FC, WB | Humanized Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOR-1273 | Hi-Affi™ Rabbit Anti-FCGR2B Recombinant Antibody (clone DS1273AB) | WB, IHC, IP, FC | Rabbit IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0586-CN | Human Anti-FCGR2B Recombinant Antibody (HPAB-0586-CN) | ELISA, WB, FC, Co-IP | Chimeric (rat/human) IgG1, κ |
| HPAB-0587-CN | Human Anti-FCGR2B Recombinant Antibody (HPAB-0587-CN) | ELISA, WB, FC, Co-IP | Humanized IgG |
| HPAB-0585-CN | Human Anti-FCGR2B Recombinant Antibody (HPAB-0585-CN) | ELISA, WB, FC, Co-IP | Chimeric (rat/human) IgG1, κ |
| HPAB-0588-CN | Human Anti-FCGR2B Recombinant Antibody (HPAB-0588-CN) | ELISA, WB, FC, Co-IP | Humanized IgG |
| HPAB-0054LY | Mouse Anti-FCGR2B Recombinant Antibody (HPAB-0054LY) | IHC, ELISA, WB, RIA | Mouse IgG |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0587-CN-S(P) | Human Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-0587-CN-S(P)) | ELISA, WB, FC, Co-IP | Humanized scFv |
| HPAB-0585-CN-S(P) | Rat Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-0585-CN-S(P)) | ELISA, WB, FC, Co-IP | Rat scFv |
| HPAB-0588-CN-S(P) | Human Anti-FCGR2B Recombinant Antibody; scFv Fragment (HPAB-0588-CN-S(P)) | ELISA, WB, FC, Co-IP | Humanized scFv |
| HPAB-0785-FY-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (HPAB-0785-FY-F(E)) | Inhib | Human Fab |
| HPAB-0786-FY-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (HPAB-0786-FY-F(E)) | Inhib | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0587-CN-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (HPAB-0587-CN-F(E)) | ELISA, WB, FC, Co-IP | Humanized Fab |
| HPAB-0585-CN-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (HPAB-0585-CN-F(E)) | ELISA, WB, FC, Co-IP | Human Fab |
| HPAB-0588-CN-F(E) | Human Anti-FCGR2B Recombinant Antibody; Fab Fragment (HPAB-0588-CN-F(E)) | ELISA, WB, FC, Co-IP | Humanized Fab |
| HPAB-0180-WJ-F(E) | Human Anti-FCGR2B Recombinant Antibody (clone NOV0281); Fab Fragment | ELISA, FC, WB | Human Fab |
| HPAB-0441-FY-F(E) | Human Anti-FCGR2B Recombinant Antibody (clone XENP15162-3D8B H1L1 IgG1 G236N/S267E); Fab Fragment | Inhib, ELISA | Human Fab |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0325-XY826 | Anti-FCGR2B Immunohistochemistry Kit | IHC | |
| VS-0525-XY2482 | Anti-Rat FCGR2B Immunohistochemistry Kit | IHC | |
| VS-0525-XY2481 | Anti-Human FCGR2B Immunohistochemistry Kit | IHC |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS13-YC387 | CytoStream™ Rat Anti-Fcgr2b Recombinant Antibody (VS13-YC387) | FC | Rat IgG2b |
| CAT | Product Name | Application | Type |
|---|---|---|---|
| VS-0425-YC343 | Recombinant Anti-FCGR2B Vesicular Antibody, EV Displayed (VS-0425-YC343) | ELISA, FC, Cell-uptake |
Specific Inquiry
Add to compare
See Our Custom Production in Action
Popular Products
Application: IF, IP, Neut, FuncS, ELISA, FC, WB
Application: Neut, ELISA, IF, IP, FuncS, FC, ICC
Application: Neut, ELISA, IF, IP, FuncS, FC, IHC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, IHC
Application: ELISA, Neut, FuncS
Application: Neut, ELISA, Inhib, ICC, WB
Application: WB, ELISA, FC, IHC, IP
Application: FC, IHC, Cyt, FuncS
-4.jpg)
Application: FC
Application: ELISA, Inhib, FuncS
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
